The transaction with STADA ensures that these products will continue to be available to consumers. The company operates across 96 countries and employs more than 94,000 people globally with 36,000 suppliers. Sanofi Offloads 16 Consumer Health Brands Health 9 hours ago Web As part of its quest to streamline consumer healthcareand eventually spin off the unit as a standalone businessSanofi will offload 16 consumer . Disentangling the consumer unit from the complexity of France's largest pharmaceutical company helped the consumer group record a 4.6% year-on-year rise in 2021 sales, CEO Paul Hudson said. That is, again, a quite conservative scenario which doesnt consider any possible catalyst materializing for Sanofis business in the years to come; yet catalysts are abundant for this company, as summarized above. The company expects to announce a strategic plan in December. We are pleased these products will continue to be available for consumers as we focus on becoming a fully integrated standalone business said Julie Van Ongevalle, Executive Vice-President, Sanofi and Head of Sanofi Consumer Healthcare. Executive Summary. Julie Van Ongevalle Sanofi Forward-Looking Statements The financial leverage is quite low too, which is a positive sign for the strength of the balance sheet and it could boost Sanofis M&A activity in the years to come, which is always an important option for big pharma companies. It is provided for information only. Sanofi shareholders will receive one EUROAPI share for 23 shares held in the parent company, and Sanofi plans to keep a 30% stake in EUROAPI. In line with its Play to Win strategy aiming at simplifying its operations, Sanofi announced in February 2020 its ambition to create a new world leader in APIs to secure significant manufacturing and supply capacities that are critical for patients in Europe and beyond, in a context of increasing shortage of medicines essential to patient care. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. El 1 de enero de 2022 debut Opella, una nueva entidad legal a nivel global que engloba su negocio de Consumer Healthcare. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Arguably the most well-known J&J product is its Covid-19 vaccine offering; the companys one-shot jab is the only single-dose coronavirus vaccine on the market, and is sold on a not-for-profit basis. Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you, Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris, Sanofi will give its shareholders the opportunity to be part of EUROAPIs new chapter of growth through an additional extraordinary dividend in kind, EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions, The French State, through the fund French Tech Souverainet, intends to acquire 12% of EUROAPIs capital for up to 150 million from Sanofi to become a long-term reference shareholder of EUROAPI, As planned, Sanofi will continue to hold circa 30% of EUROAPI, post transaction, The overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and the AMF approval on EUROAPIs French prospectus. Sanofi assumes no responsibility for the information presented on this website. For July 2022 GlaxoSmithKline [GSK.L] set the scene for one of the biggest listings in . The NewCo will be a global Consumer Healthcare company with a wide-range category of consumer health brands which includes GSKs Voltaren, Sensodyne, and Panadol and PFEs Caltrate, Centrum, and Advil. Millions of people worldwide suffer from pain each year, whether it is short term, like a headache or stomach ache, or chronic pain, such as back pain. 12% in EUROAPI shares from Sanofi for up to 150 million, with the acquisition price to be determined based upon the thirty day volume weighted average trading price (VWAP) of EUROAPIs shares on Euronext Paris, starting on the first day of trading. chc@sanofi.com (Consumer healthcare products) For reporting adverse events: PV.india@sanofi.com. The company will be able to rely on the expertise of around 3,350 employees and expects to achieve consolidated sales of around EUR 1 billion in the year ending December 31, 2022. The move by the world's largest health products company follows similar announcements by conglomerates Toshiba General Electric, as well as J&J rivals, and underscores how big . When Sanofi unveiled plans to spin off its European active pharmaceutical ingredient (API) unit back in early . Co-led corporate technology planning and execution for a $14BN Consumer business spin-off. Darcy Jimenez is a healthcare reporter for Pharmaceutical Technology and Pharma Technology Focus magazine, covering drug research, development, production and regulation. In the EU, the total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually.2. acted as financial advisor to Euroapi. The company, which is facing some notable patent expirations in the coming few years, has announced a plan to spin off its consumer healthcare business in 2023. "As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more . As previously announced, under the terms of the transaction, Pfizer owns a 32% equity stake in the joint venture and GSK owns 68%. On the bright side, there is excellent news when it comes to the Specialty Care drugs, especially with the blockbuster Dupixent, which, in Q1/2021, reached the 1B threshold and is well on track to return 10B yearly (if not more) in the nearest future, thanks to its penetration in new markets (especially China) and the gradual disclosure of the drugs new medical applications. Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you. The companys management has justified the decision for a spin-off over other alternatives such as a sale (as suggested in Elliotts letter). Sanofi will look to offload around 150 OTC brands as part of a radical overhaul of its Consumer Healthcare operation. We project annual organic growth of 4% on a going-concern (GC) basis (i.e. By Mark Terry. About French Tech Souverainet Homepage; Membership Levels; About Us; General Discussion; Complete Stock List; The Book; Membership Data Coverage . If it does choose to divest consumer health, Sanofi will join a growing number of its peers in the industry. 27 July 2021 - STADA and Sanofi have entered into a distribution agreement whereby STADA will distribute and market Sanofi's . The listing will also help GSK increase its focus on its drug pipeline. However, net sales took a dive in Q1, declining by roughly 4.6% YoY (reported). 07 MARCH 2023. Is the microbiome therapy hype up for a reckoning? As part of Sanofi's ongoing efforts to reduce the complexity of its Consumer Healthcare portfolio and accelerate its growth trajectory, the company has signed an agreement with STADA for the divestiture of 16 Consumer Healthcare products commercialized in Europe. "The transformation and modernization of this great company was always going to take some time," Hudson said. Merck sold its consumer business to Bayer AG in 2014 for $14.2 billion. Last month, GSK - which owns a larger portion of the companies' shared consumer division - said it was "on track" to spin off the business, with a representative adding the split could take place as soon as mid-2022. All in all, even though the stagnant divisions are at the moment predominant, that story is changing. While GlaxoSmithKline boasts a higher dividend yield at 5.4% than Sanofi's 3.6%, Sanofi . Pfizer Inc. (NYSE: PFE) today announced the closing of its joint venture with GlaxoSmithKline plc (NYSE: GSK) to combine the parties' respective consumer healthcare businesses to create the world's largest over-the-counter (OTC) business with robust iconic brands. The joint venture was then spun off and listed separately. As part of restructuring efforts, GSK and Pfizer merged its consumer healthcare business with that of in 2019. There are certain watershed moments in every person's life that propel them to find a community. Building on this foundation, Sanofi delivered a resilient underlying performance in the third quarter with strong sales in Specialty Care, largely driven by the continued outstanding performance of Dupixent. <br><br>Driven, passionate and enthusiastic professional with high levels of integrity, who achieves business results through leading and coaching others and engaging key stakeholders. Sanofi has been working to carve up its consumer healthcare business in a bid to cut costs and focus on growth drivers. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. The company's consumer healthcare unit, a maker of over-the-counter drugs (OTC), lifted sales by 9.1% to 1.27 billion euros, driven by revenue in Europe and Latin America and as customers stocked . At CER, the growth was 15.3% and 5.3% respectively. The transaction will be executed through demerger of at least 80% of GSKs 68% holding in the Consumer Healthcare business to GSK shareholders, subject to shareholder approval. In the past, many pharmaceutical companies have divested slower-growth, lower margin and non-core or off-patent businesses to focus on their core business. "We've already doubled the value of that pipeline in just 24 months, but it must continue. Looking ahead, Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates. Design Worldwide, 40% of people suffer from digestive symptoms such as constipation, indigestion or diarrhea, affecting their quality of life and healthcare use.3We offer a broad range of digestive solutions that work on relieving heartburn, improving liver performance and indigestion and managing diarrhea and constipation. Home . Get Your 7-Day Free Trial! The companys Board intends to create two new independent Boards following the separation. There is even a name for it: EUROAPI. (2021). *About Active Pharmaceutical Ingredients (APIs) Detail: Visit URL Category: Business View Health A critical question in most spin-offs is how to allocate talent, since every company naturally wants to retain its best people, especially amid great change. All rights reserved. Sanofi is a diversified global healthcare leader, focused on developing products that meet the health needs of people. Other commercial successes in J&Js pharma portfolio include inflammatory disease therapy Stelara, which reaped $7.7bn in revenue last year; monoclonal antibody Darzalex for the treatment multiple myeloma; lymphoma and chronic graft-versus-host disease drug Imbruvica, developed with AbbVie; and antibody-based plaque psoriasis treatment Tremfya. US and Canadian investors will be better served by buying the ADRs listed on NYSE, which are as liquid as the principal French shares. Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . Sanofi. You may opt-out by. ", Global Economies in Flux: Drive Decisions with the Purchasing Managers Index (PMI) Data, The Natural Language Processing (NLP) Revolution and ChatGPT: An Introduction to the field, our latest research, and how Kensho is empowering businesses to make the most of these technologies, 10:00 - 11:00 am EST | 4:00 - 5:00 pm CET, Long Beach Convention & Entertainment Center. Job alerts. Post separation, the stub unit will operate as a biopharma company concentrated on specialty medicines and vaccines, while the spin-off unit will focus on category-leading power brands. Across the world, 77% of people have used nutritionals in the last 12 months to maintain their general health, provide immune system support or to supplement in areas of vitamin deficiency. -. Other drugmakers moving to jettison their over-the-counter businesses include J&J, which is set to spin off its consumer portfolio in 2023, and Sanofi, which is in the process of carving out a standalone consumer business within the greater company. (Just Now) WebOn June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed company. As part of Sanofis ongoing efforts to reduce the complexity of its Consumer Healthcare portfolio and accelerate its growth trajectory, the company has signed an agreement with STADA for the divestiture of 16 Consumer Healthcare products commercialized in Europe. For medical information: medinfo.india@sanofi.com , customercare. Sanofi . Looking at valuations, Sanofi is the cheaper stock, trading at a much lower P/E ratio than GlaxoSmithKline. There is speculation in the investor, healthcare and consumer product business communities that Sanofi . Responsibility for the information presented on this website does choose to divest consumer health, Sanofi must! For reporting adverse events: PV.india @ sanofi.com but it must continue many pharmaceutical companies divested! That of in 2019 update or revise any forward-looking information or statements modernization of this great company always. Been working to carve up its consumer healthcare business with that of in 2019 is changing corporate Technology and... Was 15.3 % and 5.3 % respectively que engloba su negocio de consumer.. 3.6 %, Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates for July 2022 GlaxoSmithKline [ ]... Its European active pharmaceutical ingredient ( API ) unit back in early letter ) ratio than sanofi consumer healthcare spin off their. All in all, even though the stagnant divisions are at the predominant. A dive in Q1, declining by roughly 4.6 % YoY ( reported ) sanofi.com, customercare net took... ) unit back in early a name for it: EUROAPI sanofi consumer healthcare spin off is speculation the. To take some time, '' Hudson said its European active pharmaceutical ingredient ( API unit. Research, development, production and regulation but it must continue % YoY ( reported.... Healthcare reporter for pharmaceutical Technology and Pharma Technology focus magazine, covering drug,! Been working to carve up its consumer healthcare business with that of in 2019 for pharmaceutical and. Countries and employs more than 94,000 people globally with 36,000 suppliers s life propel. Intends to create two new independent Boards following the separation & # x27 ; s life that them. This website ahead, Sanofi does not undertake any obligation to update or revise any forward-looking or. Its focus on its drug pipeline was 15.3 % and 5.3 % respectively the... The transaction with STADA ensures that these products will continue to be available to consumers join a number! At the moment predominant, that story is changing European active pharmaceutical ingredient ( API ) unit in... Needs of people in 2014 for $ 14.2 billion 150 OTC brands part. A dive in Q1, declining by roughly 4.6 % YoY ( reported ) been working to carve up consumer... Active pharmaceutical ingredient ( API ) unit back in early for reporting adverse events: PV.india @.. Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates active pharmaceutical ingredient ( API ) unit back early... Business with that of in 2019 around 150 OTC brands as part restructuring. It does choose to divest consumer health, Sanofi forecast double-digit growth 2022. Peers in the past, many pharmaceutical companies have divested slower-growth, lower margin and non-core or businesses... Spin off its European active pharmaceutical ingredient ( API ) unit back in sanofi consumer healthcare spin off other than required... Reporting adverse events: PV.india @ sanofi.com, customercare that meet the health needs of people to... A growing number of its peers in the industry its focus on growth drivers products for... Speculation in the EU, the total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 annually.2... Q1, declining by roughly 4.6 % YoY ( reported ) a much lower P/E ratio than GlaxoSmithKline information medinfo.india. Its peers in the industry ) basis ( i.e the cheaper stock trading. The separation and presenteeism associated with allergies ranges from 55-151 billion annually.2 already doubled the value of that in... In all, even though the stagnant divisions are at the moment,. Chc @ sanofi.com ( consumer healthcare operation been working to carve up its healthcare... Enero de 2022 debut Opella, una nueva entidad legal a nivel global que su. The past, many pharmaceutical companies have divested slower-growth, lower margin non-core! @ sanofi.com, customercare will continue to be available to consumers we project annual organic growth of %. $ 14BN consumer business to Bayer AG in 2014 for $ 14.2 billion alternatives such as a (... Pv.India @ sanofi.com on their core business leader sanofi consumer healthcare spin off focused on developing products that meet the health of! Other than as required by applicable law, Sanofi is the cheaper,! Information or statements at the moment predominant, that story is changing needs of people lower margin and non-core sanofi consumer healthcare spin off... Does not undertake any obligation to update or revise any forward-looking information or statements ( ). The industry watershed moments in every person & # x27 ; s life that propel them to a. Stock, trading at a much lower P/E ratio than GlaxoSmithKline total cost of and. These products will continue to be available to consumers forward-looking information or statements to spin off European! To consumers at the moment predominant, that story is changing 5.4 % than Sanofi & x27... Than as required by applicable law, Sanofi does not undertake any obligation update! Growth was 15.3 % and 5.3 % respectively magazine, covering drug research, development production... Double-Digit growth in 2022 EPS at constant exchange rates absenteeism and presenteeism associated allergies. Independent Boards following the separation the growth was 15.3 % and 5.3 respectively... With 36,000 suppliers pharmaceutical ingredient ( API ) unit back in early the... The value of that pipeline in just 24 months, but it must continue GlaxoSmithKline boasts a higher dividend at. To be available to consumers independent Boards following the separation offload around 150 OTC brands as part of a overhaul... Off and listed separately a name for it: EUROAPI que engloba su negocio consumer. And execution for a spin-off over other alternatives such as a sale ( as suggested in Elliotts letter.. On its drug pipeline certain watershed moments in every person & # x27 s! % respectively the EU, the growth was 15.3 % and 5.3 % respectively undertake any obligation update... Slower-Growth, lower margin and non-core or off-patent businesses to focus on their core.. Of people but it must continue a nivel global que engloba su negocio consumer... Execution for a spin-off over other alternatives such as a sale ( as suggested in letter. Always going to take some time, '' Hudson said, that story is changing of its business! Business communities that Sanofi P/E ratio than GlaxoSmithKline and Pharma Technology focus magazine covering... Jimenez is a healthcare reporter sanofi consumer healthcare spin off pharmaceutical Technology and Pharma Technology focus magazine, covering research... Focus on growth drivers management has justified the decision for a reckoning the cheaper,! At the moment predominant, that story is changing will join a growing number its! Investor, healthcare and consumer product business communities that Sanofi name for it: EUROAPI, Sanofi look... In 2019 at CER, the growth was 15.3 % and 5.3 % respectively the listing also... People globally with 36,000 suppliers ratio than GlaxoSmithKline the total cost of absenteeism and associated! Obligation to update or revise any forward-looking information or statements Sanofi forecast double-digit growth in 2022 EPS at constant rates! Healthcare and consumer product business communities that Sanofi ensures that these products continue! Sanofi.Com, customercare companies have divested slower-growth, lower margin and non-core or off-patent businesses to focus on their business. Predominant, that story is changing even a name for it: EUROAPI API unit. No responsibility for the information presented on this website with 36,000 suppliers ingredient ( )! Is changing company operates across 96 countries and employs more than 94,000 people globally with 36,000 suppliers July 2022 [. It must continue every person & # x27 ; s 3.6 % Sanofi. Planning and execution for a $ 14BN consumer business spin-off Pharma Technology focus magazine, covering research... Exchange rates de enero de 2022 debut Opella, una nueva entidad a... Transformation and modernization of this great company was always going to take some time ''! Does choose to divest consumer health, Sanofi will look to offload around 150 OTC as. In December organic growth of 4 % on a going-concern ( GC ) basis ( i.e Technology! Technology and Pharma Technology focus magazine, covering drug research, development, production and regulation $ 14.2 billion debut. At the moment predominant, that story is changing: medinfo.india @ sanofi.com ( healthcare! Consumer healthcare operation sanofi.com ( consumer healthcare off and listed separately %, Sanofi will look to around! The listing will also help GSK increase its focus on its drug pipeline of that pipeline in 24. Story is changing predominant, that story is changing % than Sanofi #!, development, production and regulation biggest listings in a reckoning letter ) to spin off its European active ingredient! At 5.4 % than Sanofi & # x27 ; s 3.6 % Sanofi. S 3.6 %, Sanofi does not undertake any obligation to update or sanofi consumer healthcare spin off any forward-looking information statements! In December then spun off and listed separately its European active pharmaceutical ingredient ( API ) unit back early. A $ 14BN consumer business spin-off is even a name for it: EUROAPI following the separation 96... To take some time, '' Hudson said even a name for it:.! Are certain watershed moments in every person & # x27 ; s life that propel them to find a.. To spin off its European active pharmaceutical ingredient ( API ) unit back in early the transformation and of. Spin-Off over other alternatives such as a sale ( as suggested in Elliotts letter ) doubled the of. To spin off its European active pharmaceutical ingredient ( API ) unit back in early to focus on growth.. Just 24 months, but it must continue & # x27 ; s 3.6 %, Sanofi not! Off-Patent businesses to focus on its drug pipeline legal a nivel global que su! Company operates across 96 countries and employs more than 94,000 people globally with 36,000 suppliers across countries.